RN1201 injection for hard-to-treat autoimmune diseases
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests an investigational injection called RN1201 for people whose autoimmune disease (like lupus, myasthenia gravis, or immune thrombocytopenia) has not responded to standard therapies. The goal is to see if it can better control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a confirmed autoimmune disease (like ITP, lupus, multiple sclerosis, etc.) that has lasted at least 6 months.
- Standard treatments have not worked well enough, and you've been on a stable dose for over 2 weeks.
- Your disease is moderate to severe, and your major organs (heart, lungs, liver, kidneys, bone marrow) are working well enough.
- You agree to use effective birth control for 24 months after starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called RN1201 for people with antibody-mediated diseases, specifically two types of blood disorders: platelet transfusion refractoriness (PTR) and immune thrombocytopenia (ITP) that haven't responded to standard treatments. The goal is to see if RN1201 can help control these conditions.
This trial tests a new immunotherapy, RN1201, for people with certain blood cancers (like multiple myeloma, leukemia, or lymphoma) that have come back or not responded to standard treatments. It aims to see if this treatment can help when other options have stopped working.
This trial tests a new drug called RN1201 as a first-line treatment for multiple myeloma, a blood cancer. The study aims to see if it is safe and effective for patients who have never been treated for this condition before.
This early-stage study tests an experimental treatment that uses engineered immune cells (called CAR natural killer cells) to calm overactive immune responses in people with moderate to severe autoimmune diseases that have not fully responded to standard treatments. It aims to offer a new option for patients who have not gotten enough benefit from usual therapies.
This trial tests a new cell therapy called UTAA91 for people with autoimmune diseases that have not responded to standard treatments. It aims to see if this treatment can help control the disease.
This trial tests a new mRNA treatment called HN2301 for people with autoimmune diseases like lupus, scleroderma, or rheumatoid arthritis. It aims to see if the treatment is safe and helps control the disease.
Hear when a new Autoimmune Diseases Refractory to Standard Therapies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.